Our CEO Dr. Edward Kaye sat down with Brad Loncar of @BiotechTVHQ to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA-based medicines. Watch here:

The Stoke team is heading to International League Against Epilepsy’s 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: investor.stoketherapeutics.com/news-releases/… #EEC2024 #ILAE

Today we announced upcoming investor conference presentations at H.C. Wainwright & Co.’s 26th Annual Global Investment Conference and Cantor Fitzgerald’s 2024 Global Healthcare Conference. Learn more: investor.stoketherapeutics.com/news-releases/… #CantorHCC #Biotech #innovation #investment

Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics investor.stoketherapeutics.com/news-releases/…

Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome. investor.stoketherapeutics.com/news-releases/… #ILAE #EEC2024 International League Against Epilepsy

Today on #SUDEPActionDay2024, we’re raising awareness about Sudden Unexpected Death in Epilepsy (#SUDEP) and the importance of understanding its risks. By supporting ongoing research, we can help improve safety for those affected. Learn more: sudepactionday.org

Living with #DravetSyndrome takes resilience. Not only from patients but also from the caregivers who support them every day. This #FamilyCaregiversMonth, we honor these strong caregivers. For tools and resources visit Dravet Syndrome Foundation: dravetfoundation.org/caregiver-reso…

It’s Epilepsy Awareness Day at Disneyland! Stoke is proud to attend this year’s event and are grateful for the organizers for all their efforts in raising awareness and sharing knowledge. #ThePurplestPlaceOnEarth #EpilepsyAwarenessDayAtDisneyland

Stoke Therapeutics management will present at the Jefferies London Healthcare Conference today at 6:30am EST (11:30am GMT). A live webcast of the presentation by our CEO, Dr. Edward Kaye, will be available on our website: bit.ly/3ASYKKz #JefferiesHealthcare

Today on Autosomal Dominant Optic Atrophy (ADOA) Awareness Day, Stoke is standing alongside individuals and families affected by #ADOA. This condition brings unique challenges to those who live with it. We applaud the ADOA Association and Cure ADOA Foundation for their ongoing advocacy.

This Thanksgiving, we're grateful for the dedication, teamwork, and shared vision that drive us forward every day. Our team's commitment to making a difference for patients and families continues to inspire us. #HappyThanksgiving from all of us at Stoke, to you and yours!

We’re presenting new clinical data from our Dravet syndrome program at #AES2024. These updates highlight progress in reducing seizures and improving cognition and behavior. Learn more: investor.stoketherapeutics.com/news-releases/…

Today, our investigational new medicine for #DravetSyndrome received U.S. FDA Breakthrough Therapy designation. With no approved therapies, this designation highlights the urgent need for new solutions and brings hope to patients with Dravet. Learn more: investor.stoketherapeutics.com/news-releases/…

Save the date for our Investor & Analyst Virtual Educational Event, tomorrow 12/9, to explore #DravetSyndrome, current treatments, and the potential of disease-modifying medicines. Register now to hear from leading clinicians & patient advocates: edge.media-server.com/mmc/p/bv6h2oxs

This holiday season, we’re reflecting on the resilience and strength of the patients and families who inspire us every day. To our team, partners, and community—thanks for your support and dedication. From us at Stoke, happy holidays and best wishes for a bright new year!

Stoke has achieved alignment with global regulators for the first-ever Phase 3 study of a potential disease-modifying medicine for Dravet syndrome. This offers a promising opportunity to change how the disease is treated. Learn more: investor.stoketherapeutics.com/news-releases/…

Stoke Therapeutics CEO, Dr. Edward Kaye, is scheduled to present at #JPM2025 on Wednesday, January 15. Save the date to join the live audio webcast or access the replay afterward: jpmorgan.metameetings.net/events/healthc… #Biotech #Healthcare #JPM25

Don’t miss CEO Dr. Edward Kaye take the stage at #JPM2025. Tune in to learn more about our entry to late-stage development in Dravet syndrome and future potential for the company's platform to address additional diseases of the CNS and the eye. jpmorgan.metameetings.net/events/healthc…

Stoke was proud to participate in the Rare Advocate Development (RAD) Brain Workshop in NYC this week. Thank you to the organizers, Rare Epilepsy Network, Global Genes, and Mahzi Therapeutics for empowering patient advocates to advance therapeutic options.

Stoke has entered into a collaboration with Biogen to develop and commercialize our lead therapeutic candidate for the treatment of #Dravetsyndrome. Learn more: investor.stoketherapeutics.com/news-releases/…